LEXINGTON, Ky. (Dec. 8, 2020) – It has been nearly one year since the SARS-CoV-2 coronavirus changed the world. With millions of people infected and over a quarter million dead in the United States, the novel coronavirus continues its pervasive hold on our health and well-being.
After months of stress, frustration and uncertainty, people are itching to travel and visit loved ones during the height of the holiday season, despite increasing cases of COVID-19. As the virus continues to dominate news coverage, people are clinging to the anticipation of promising vaccine trials from Pfizer, Moderna and several other companies. How will these vaccines, and potentially others still to come, change the course of the pandemic? Will we be able to return to normal and how long could that take?
On this episode of Behind the Blue, we speak with Vincent Venditto, an assistant professor in the University of Kentucky College of Pharmacy’s Department of Pharmaceutical Science, and Brooke Hudspeth, an associate professor and Chief Practice Officer for the University of Kentucky College of Pharmacy. In part two of our interview with Vince and Brooke, we discuss who exactly takes part in vaccine trials, the issues those trials may run into, when to expect some type of herd immunity and more.
For questions or comments about this or any other episode of "Behind the Blue," email BehindTheBlue@uky.edu or tweet your question with #BehindTheBlue.
To discover what’s wildly possible at the University of Kentucky, click here.